Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard L Piekarz

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Cancer Journal (Sudbury, Mass.)|May 4, 2007
Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?Susan E Bates, Richard L Piekarz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Epigenetic modifiers: basic understanding and clinical developmentRichard L Piekarz, Susan E Bates
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2015
CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic PortfolioSusan E Bates, Robert W Robey, Richard L Piekarz
Cancer Journal (Sudbury, Mass.)|April 28, 2007
Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapyRichard L Piekarz, Dan L Sackett, Susan E Bates
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Challenges of evaluating the cardiac effects of anticancer agentsSusan E Bates, Douglas R Rosing, Tito Fojo, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 30, 2004
Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometryKyunghwa Hwang, Richard L Piekarz, Susan E Bates, et al.
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Clinical Toxicities of Histone Deacetylase InhibitorsSrividya Subramanian, Susan E Bates, John J Wright, et al.
Cardiovascular Drugs and Therapy|May 11, 2005
Effect of a histone deacetylase inhibitor on human cardiac massYukitaka Shizukuda, Richard L Piekarz, Susan E Bates, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)Robert W Robey, Zhirong Zhan, Richard L Piekarz, et al.
Clinical Journal of Oncology Nursing|March 31, 2012
Romidepsin: a new drug for the treatment of cutaneous T-cell lymphomaRobin Frye, Mary Myers, Karen C Axelrod, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Cancer Journal (Sudbury, Mass.)|May 4, 2007
Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?Susan E Bates, Richard L Piekarz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Epigenetic modifiers: basic understanding and clinical developmentRichard L Piekarz, Susan E Bates
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2015
CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic PortfolioSusan E Bates, Robert W Robey, Richard L Piekarz
Cancer Journal (Sudbury, Mass.)|April 28, 2007
Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapyRichard L Piekarz, Dan L Sackett, Susan E Bates
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Challenges of evaluating the cardiac effects of anticancer agentsSusan E Bates, Douglas R Rosing, Tito Fojo, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 30, 2004
Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometryKyunghwa Hwang, Richard L Piekarz, Susan E Bates, et al.
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Clinical Toxicities of Histone Deacetylase InhibitorsSrividya Subramanian, Susan E Bates, John J Wright, et al.
Cardiovascular Drugs and Therapy|May 11, 2005
Effect of a histone deacetylase inhibitor on human cardiac massYukitaka Shizukuda, Richard L Piekarz, Susan E Bates, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)Robert W Robey, Zhirong Zhan, Richard L Piekarz, et al.
Clinical Journal of Oncology Nursing|March 31, 2012
Romidepsin: a new drug for the treatment of cutaneous T-cell lymphomaRobin Frye, Mary Myers, Karen C Axelrod, et al.
Pageof 4